The purpose of this study is to couple a cellular bone homeostasis model with the pharmacokinetics (PK) and mechanism of action of denosumab, an inhibitor of receptor activator of nuclear factor-κB ligand, to characterize the time course of serum Ntelopeptide (NTX), a bone resorption biomarker, following single escalating doses in multiple myeloma (MM) patients. Mean PK and median serum NTX temporal profiles were extracted from a previously conducted randomized, double-blind, double-dummy, active-controlled, multicenter study including 25 MM patients receiving escalating denosumab doses. Nonlinear denosumab PK profiles were well described by a targetmediated disposition model that includes rapid binding of drug to its pharmacological target. Fixed PK profiles were integrated into a previously reported theoretical cellular model of osteoblast-osteoclast interactions, and the NTX concentrations were linked to a resorbing active osteoclast (AOC) pool by a nonlinear transfer function. Reasonable fits were obtained for the NTX profiles from maximum likelihood estimation using the final model. Transfer function parameters, including the basal NTX level and the AOC concentration producing 50% of maximal NTX production, were estimated with good precision as 5.55nM and 1.88x10 -5 pM. An indirect response model for inhibition of NTX production by denosumab was also used to characterize the data. Although this model adequately characterized the pharmacodynamic data, simulations conducted with the full model reveal that a cellular model coupled with clinical data has the distinct advantage of not only quantitatively describing data but also providing new testable hypotheses on the role of cellular system variables on drug response.
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Multiple Myeloma (MM) is the second most prevalent blood cancer after nonHodgkin's lymphoma, affecting around 50,000 individuals, with approximately 15,000 new cases reported each year in the United States alone (Hideshima et al., 2003) . The disease is characterized by the infiltration of malignant plasma cells in the bone marrow that results in genomic instability and changes in the bone-marrow microenvironment, whereby patients often develop osteolytic lesions that cause fractures and severe bone pain (Kyle and Rajkumar, 2004; Hideshima et al., 2007) . These lesions are a result of imbalanced bone remodeling with increased bone degradation and decreased bone formation due to many factors, including the overexpression of receptor activator of nuclear factor-κB ligand (RANKL) and down regulation of its decoy receptor, osteoprotegrin (OPG) (Kyle and Rajkumar, 2004; Matsumoto and Abe, 2006) .
The cellular components of bone remodeling are the osteoblasts, derived from the mesenchymal stem cells and responsible for bone formation, and the osteoclasts, derived from hematopoietic stem cells, causing bone degradation/resorption (Filvaroff and Derynck, 1998) . The binding of RANKL, a tumor necrosis factor (TNF)-related cytokine
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TGF-β, TNF-α, IL-1, IL-6, PTH and estrogen) that contribute to bone homeostasis (Roodman, 1999; Hofbauer et al., 2000; Boyle et al., 2003) .
Appreciation for the RANK-RANKL-OPG pathway in bone remodeling has provided novel targets for therapeutics. Denosumab (AMG 162; Amgen Inc., Thousands Oaks, CA) is a human IgG 2 monoclonal antibody that binds to RANKL with high affinity and specificity inhibiting RANKL-RANK interaction. Initial clinical trials in MM and other bone disorders have demonstrated denosumab to effectively decrease bone resorption rapidly and for a sustained period of time with minimal side effects (Bekker et al., 2004; Body et al., 2006) . Currently, denosumab has entered phase III clinical trials for the treatment of bone loss in postmenopausal osteoporosis, prostrate and breast cancer, and multiple myeloma (Schwarz and Ritchlin, 2007) .
Limited PK/PD analyses of denosumab using noncompartmental approaches have been reported. Since rodent RANKL is not recognized by this drug, preclinical data have been limited to studies conducted in cynomolgus monkeys (Kostenuik, 2005) . Initial phase I studies in MM, breast cancer patients, and postmenopausal women, reveal dosedependent pharmacokinetics of the drug following subcutaneous (SC) administration (Bekker et al., 2004; Body et al., 2006) . The drug exhibited rapid and prolonged absorption with the average maximum serum concentrations occurring between 7 and 21 days post-dose and a relatively long elimination half-life of 33.3 days in MM patients.
On the other hand, mathematical models capable of describing various factors controlling bone homeostasis on the cellular level have been developed. A simple model by Komarova and coworkers (2003) describes the autocrine/paracrine regulation of osteoclasts and osteoblasts. Martin and Buckland-Wright (2004) developed a model that includes the RANK-RANKL-OPG pathway; however, its primary purpose is to describe in vitro bone resorption. A model by Lemaire and colleagues (2004) , describes the tight coupling between osteoblasts and osteoclasts during the remodeling process and also includes several key regulatory factors including the essential RANK-RANKL-OPG pathway. This cellular bone homeostasis model exhibits good semi-quantitative correlation with experimental data from the literature and can be used to simulate changes associated with disease conditions. This model was subsequently adapted to understand TNF-α induced bone loss in mice (Iqbal et al., 2006) .
The purpose of this report is to integrate the denosumab PK with the cellular bone homeostasis model and to incorporate drug effects on the RANK-RANKL-OPG pathway in order to capture the time course of NTX in MM patients. The pharmacokinetics of denosumab is characterized over a range of doses using a target-mediated drug disposition model. The pharmacodynamic data are also characterized by a basic indirect response model with denosumab inhibiting the production of serum NTX.

Methods
Data Source. Mean PK and absolute median PD data were digitized (Graph Digitizer version 1.9) from a previously conducted randomized, double-blind, double-dummy, active-controlled, multicenter study that included 25 MM patients (Body et al., 2006) Patients received either 0.1, 0.3, 1.0 or 3.0 mg/kg of denosumab subcutaneously and blood samples were obtained at 1, 2, 4, 8 and 24 hours after drug administration and then weekly up to 84 days.
Pharmacokinetics.
The time-course of serum denosumab concentrations was characterized using a rapid binding model of target-mediated drug disposition ( Fig. 1 ) (Mager and Krzyzanski, 2005) . Drug is absorbed into the central compartment (C P , V c ) from the subcutaneous injection site by a first order rate process (k a ). In the central compartment, drug reversibly binds to the free ligand to form the drug-ligand complex (RC) which is subsequently internalized (k int ). Free drug is also eliminated from the central compartment at a first-order rate (k el ). The prolonged absorption phase and the absence of i.v. data allowed for neglecting the distribution of the drug to a non-specific tissue compartment and thus reduced the number of parameters in this model.
The key feature of this model is that it assumes rapid binding of the drug to its pharmacological target (free ligands) with high affinity. Thus it is assumed that the free drug (C p ), free ligand (R), and drug-ligand complex (RC) are related
, where k on and k off are the second-and first-order rates of association and dissociation and K D is the equilibrium dissociation constant. It was also assumed that the total ligand concentration (R tot ) representing the sum of free ligand and drug-ligand complex, RC R R + = tot , was time-invariant, the validity of which has been This article has not been copyedited and formatted. The final version may differ from this version.
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where
) is the total drug concentration representing the sum of both free drug and the drug-ligand complex, and V c /F is the volume of the central compartment adjusted for bioavailability. The initial condition for Equation 1 is set to zero.
Pharmacodynamics -Basic Indirect Response Model.
A compartmental analysis of the pharmacodynamic data was performed using a well established basic indirect response model (Dayneka et al., 1993; Sharma and Jusko, 1998) . This model assumes that denosumab has an inhibitory action on the production rate of the response variable, which is consistent with known mechanism of action of the drug. The rate of change of NTX over time can be represented as:
where k in is the apparent zero-order production rate of the response, k out is the first-order rate of loss of response, I max is the maximal fractional extent of inhibition, and IC 50 is the drug concentration producing 50% of maximal inhibition. The initial condition for is illustrated in Figure 2 . The details of the cellular model can be obtained from the original publication (Lemaire et al., 2004) as only key features relevant to our PK/PD analysis are described here. and thus the amount of RANKL in the system is proportional to the active osteoblasts.
The RANK-RANKL interaction is also controlled by OPG which is produced and released by the responding osteoblasts. Similarly the proportion of osteoblasts is controlled by the active osteoclasts through the action of TGF-β which is released from the bone matrix during bone resorption by active osteoclasts.
The influence of PTH on the RANK-RANKL-OPG axis has also been incorporated. PTH receptors are assumed to be present on both active and responding osteoblasts. Binding of PTH to the receptors on active osteoblasts and responding osteoblasts stimulates the production of RANKL and inhibits the production of OPG respectively. The net effect is to enhance the RANK-RANKL interaction and consequently increase the active osteoclast pool.
This paper extends the cellular bone homeostasis model (Lemaire et al., 2004) described above by incorporating the disposition and mechanism of action of denosumab decrease would be reflected as a decrease in the levels of serum NTX, which is a byproduct of bone resorption by active osteoclasts.
The governing equations for the concentration of the state variables, the responding osteoblasts (C ROB ), the active osteoblasts (C AOB ), and the active osteoclasts (C AOC ) are as follows:
where D These account for three separate binding reactions as shown in Scheme (1). While the surface density of RANKL was assumed to be constant to obtain the pharmacokinetic profile of denosumab, the production (p L ) and elimination (e L ) of RANKL is considered in the derivation of RANK occupancy (Lemaire et al., 2004) . For simplicity, the internalization of the drug-ligand complex has been ignored. It is assumed that the concentration of RANK receptors is a constant throughout the bone remodeling process as they are present on an undiminished supply of osteoclast precursors. The production (p O ) and elimination (e O ) of OPG is considered specifically and the production/elimination of denosumab is described by the PK model (Eqs. 1 and 2). The kinetic equations for these binding reactions are provided in Data Supplement (online).
Binding reactions in biological systems are usually much faster than the time required for cell populations to change. Thus, the receptors/ligands are considered to be at a pseudo-steady-state during bone remodeling. Applying the pseudo-steady state assumption along with the expressions for the production/ elimination of RANKL and This article has not been copyedited and formatted. The final version may differ from this version. 
) can be calculated as (online supplemental data):
where r L is the net rate of RANKL production , P L K is the maximum number of RANKL attached on each surface, P π is the occupancy of the PTH receptor, and I L is the rate of increase in RANKL through pathways independent of bone remodeling. External administration would represent one such pathway. The expressions for P π , O, and the receptor occupancy of TGF-β, are listed in Data Supplement (online).
The expression derived for L π (Eq. 7) suggests that increasing doses of denosumab would cause a decrease in L π that would result in a decrease in the active osteoclast pool (Eq. 6). Also in the absence of drug (C P = 0), L π reduces to the derivation presented in the original model (Lemaire et al., 2004) .
The active osteoclast is linked with serum NTX concentration using the following non-linear transfer function:
where E b is the basal NTX concentration corresponding to very low levels of active osteoclasts in the system, NTX SS is the steady state baseline value of NTX, n is the Hill coefficient, and EC 50 is the osteoclast concentration producing 50% of the maximal NTX production.
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and R SS .
The cellular bone homeostasis model ( 
where the superscript represents the steady state values of the variables.
The initial parameter estimates for the indirect response model were calculated as described elsewhere (Sharma and Jusko, 1998 for 60 days) to increase the concentrations of active osteoclasts, responding osteoblasts, and active osteoblasts is shown in Figure 6A . This increase is attributed to the increase in RANKL and decrease in OPG in the system due to PTH. In contrast, the cellular concentration-time profiles for the cases of active osteoclast input and depletion obtained in this study were significantly different from the original profiles. The profile for the effect of active osteoclast administration (0.0001pMday -1 ) is shown in Figure 6B .
Simulations with original parameters show a rapid increase in active osteoclasts followed by an increase in responding osteoblasts. This increase in the responding osteoblasts is due to the increase in the levels of TGF-β which stimulates the differentiation of progenitors into responding osteoblasts and inhibits their differentiation into active osteoblasts. The active osteoblasts show an initial decline due to the inhibitory action of TGF-β followed by an increase due to the increase of responding osteoblasts in the system. This effect was not captured with the new parameters and the concentrations remained at their steady-state baseline values (Fig. 6B) Simulations were performed to assess the effect of multiple-dosing and a theoretical time-dependent increase in RANKL in the system on the pharmacodynamics of denosumab. Subcutaneous dosing every 90 days for the four dose levels (0.1, 0.3, 1.0, 3.0 mg/kg) was considered. Multiple-dosing in the first case revealed a further reduction in the maximum response for the second dosing cycle and attainment of steady-state conditions thereafter (Fig. 6C) . The response was dose-dependent and, for the highest dose, the maximum response was close to the value of E b , suggesting extremely low levels of active osteoclasts in the system. A theoretical disease progression was introduced using a linear time-dependent increase in RANKL (I L (t) = m L t in Eq. 7) for the second case which otherwise was set as zero. This increase in RANKL is reflective of an increase independent of the bone remodeling process. Recent studies have shown myeloma cells to express RANKL which would represent one such pathway for its upregulation (Sezer et al., 2002; Heider et al., 2003) . In this multiple dosing scheme, a steady rise in the serum NTX concentration was observed with time for every dosing cycle (Fig. 6D ). For the lowest dose the serum concentration seems to asymptotically approach a value of approx. 9 nM, equal to the baseline condition.
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Discussion
The primary objective of this study was to demonstrate that a cellular systems model can be effectively linked with the pharmacokinetics and mechanism of action of a drug to characterize the time-course of the pharmacodynamic response. To this end, the pharmacokinetics of denosumab was integrated with a cellular bone homeostasis model (Lemaire et al., 2004) (Fig. 2 ) and used to characterize the temporal profiles of serum NTX following drug administration in MM patients.
Noncompartmental analysis of the plasma concentration profiles of denosumab showed an apparent trend for decreasing clearance (CL/F) and steady-state volume of distribution (V SS /F) with increasing dose (Table 1) . These nonlinear properties might be attributed to saturable binding with RANKL or other factors including ligand downregulation. Although it was assumed that R tot (the free and the bound ligand) remained constant, the target-mediated model (Fig. 1) captured the pharmacokinetic profile of denosumab reasonably well (Fig. 3) . Denosumab concentrations at later time points were slightly under-predicted (1.0 mg/kg) and over-predicted (3.0 mg/kg) for the higher doses.
However, since the primary goal of the PK analysis was to obtain a reasonable driving function for the PD, additional parameters in attempting to describe other pathways (for example, ligand turnover) were not warranted for these minor deviations. Also, the prolonged absorption phase of the drug precluded the assessment of the distribution of the drug to a peripheral tissue compartment, thus reducing the number of parameters to be estimated. However, it is important to note that a tissue compartment would perhaps be needed to characterize intravenous and SC data simultaneously.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2) characterizes the time course of serum NTX in multiple myeloma patients reasonably well (Fig. 5 ) and the parameters were estimated with good precision (Table 3 ). There were slight deviations in the predicted pharmacodynamic profiles that may be due to several factors including the variability in NTX concentrations and the use of median data. The time course of serum NTX was also characterized independently by the indirect response model where the production of response is inhibited by the drug (Fig. 4) . The fits for both the models (cellular and response. A theoretical disease progression was simulated by increasing RANKL independent of the bone remodeling process, revealing a steady increase in serum NTX levels even for the highest dose administered once every 3 months (Fig. 6D) , whereas NTX levels were suppressed and maintained around 6 nM when RANKL was not increased (Fig. 6C) . RANKL was increased in the system because multiple myeloma patients have an upregulated RANKL (Kyle and Rajkumar, 2004; Matsumoto and Abe, 2006 ) and myeloma cells also express RANKL (Sezer et al., 2002; Heider et al., 2003) .
These simulations demonstrate the added value of linking physiological systems with PD models, namely the capability to incorporate disease effects and other factors that may influence short-and long-term responses to a drug. Although data on the long-term clinical effects of denosumab are not yet available, the approach outlined in this study might prove useful in interpreting outcomes and sources of inter-individual variability.
Current efforts are underway to link the model to biomarkers from pre-clinical models of MM.
The work we have presented begins to highlight the interdependence of bone biology and endocrine system components (e.g. PTH) to maintain homeostasis. The relationships between cell lines, cytokines either produced by, or implicated in, osteoclast and osteoblast functions, calcium balance requirements to sustain life, the role of PTH, and other organs that mediate calcium balance is complex. Therefore, it is reasonable that models will require increasing levels of complexity if they are going to be able to generalize across diseases and therapeutic interventions. A model aimed at condensing the available literature into a single physiological model for bone was recently presented (Peterson and Riggs, 2007) . That model utilized the same cellular concepts as this work described by Lemaire and colleagues (2004) , and took a further step of introducing many This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on May 6, 2008 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from of the mentioned organ and cytokine components in order to describe bone biology from the perspective of calcium balance, with attention on generalizability and ability to predict certain disease effects. Whether it will present a reasonable construct for exploring disease effects such as those seen in MM remains to be seen. At a minimum it represents an application of systems biology modeling to bone physiology, and supports the approach demonstrated here in this work.
In conclusion, an integrated cellular bone homeostasis model was developed and 
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